Roeland Nusse - Mar 7, 2024 Form 4 Insider Report for BIO-TECHNE Corp (TECH)

Role
Director
Signature
Andrew Nick as Attorney-in-Fact for Roeland Nusse pursuant to Power of Attorney previously filed
Stock symbol
TECH
Transactions as of
Mar 7, 2024
Transactions value $
-$800,627
Form type
4
Date filed
3/11/2024, 04:04 PM
Previous filing
Oct 30, 2023
Next filing
Oct 28, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TECH Common Stock Sale -$801K -10.4K -19.44% $76.98 43.1K Mar 7, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding TECH Stock Options (Right to Buy) 17K Mar 7, 2024 Common Stock 17K $21.84 Direct
holding TECH Stock Options (Right to Buy) 15.9K Mar 7, 2024 Common Stock 15.9K $25.30 Direct
holding TECH Stock Options (Right to Buy) 12.5K Mar 7, 2024 Common Stock 12.5K $31.26 Direct
holding TECH Stock Options (Right to Buy) 7.59K Mar 7, 2024 Common Stock 7.59K $44.96 Direct
holding TECH Stock Options (Right to Buy) 8.04K Mar 7, 2024 Common Stock 8.04K $50.41 Direct
holding TECH Stock Options (Right to Buy) 6.03K Mar 7, 2024 Common Stock 6.03K $63.92 Direct
holding TECH Stock Options (Right to Buy) 2.53K Mar 7, 2024 Common Stock 2.53K $128.81 Direct
holding TECH Stock Options (Right to Buy) 3.46K Mar 7, 2024 Common Stock 3.46K $73.94 Direct
holding TECH Stock Options (Right to Buy) 3.94K Mar 7, 2024 Common Stock 3.94K $61.51 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.955 to $77.11, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 The option vests on the earlier of the one year anniversary of the grant date (10/26/2023) or the date of Bio-Techne's 2024 annual meeting of shareholders.